Roots achieves further success with RZTO heating technology

|

Published 21-FEB-2020 09:49 A.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Roots announced a further milestone today, this time pertaining to its proof of concept (POC) study on vegetables from the diverse Malvaceae botanical family.

There are a number of economically important species under the Malvaceae family, including cotton (various Gossypium species), cacao (Theobroma cacao), linden (Tilia species), durian (Durio species), Hibiscus, and okra (Abelmoschus esculentus).

The Malvaceae family contains ~243 genera and at least 4,225 different species of herbs, shrubs, and trees.

Roots has been testing its Root Zone Temperature Optimisation (RZTO) heating technology on the okra plant.

The company has successfully increased the yield of Okra plants by 78% under extreme cold weather.

The successful proof of concept (POC) study conducted in Southern Israel, was completed over a four month period with the technology activated only during the winter months to heat the roots zone of the Okra.

The system was able to maintain a stable root temperature of 22C despite air temperature fluctuating between 25C during the day and 8C during the night (see table below).

Roots CEO and Chairman Boaz Wachtel said of this latest success, "This successful POC potentially opens up another large market for Roots. Okra is part of the Malvaceae plant group with over 4,225 species so we will be looking to conduct POCs on other plants within the Malvaceae family.

“We are now carefully assessing the larger regions for Okra cultivation and we will be actively targeting key growers in these regions to share the POC results. The scope for the RZTO technology across plant groups and different geographies is only just being realised.”

Okra itself represents a large market opportunity with its seed market growing at a compound annual growth rate (CAGR) of 9.8% and expected to be valued at ~US$352m by 2023.

This may have something to do with its health benefits. It contains magnesium, which can help prevent osteoporosis, is a good source of folate, which helps prevent neural tube birth defects and contains vitamin A, which helps keep eyes healthy.

Okra also contains thiamin, which is important for brain function.

Today’s news continues a solid run of news flow for Roots, which in the last couple of weeks alone has seen the company extend an important sales agreement with Israeli medical cannabis producer, Barlev Group.

Barlev Group signed a further A$30,000 order for Roots RZTO technology.

Italian producer Cairo & Doutcher has also been using the technology with great success and last week signed an exclusive binding agreement to sell a minimum of five Root Zone Temperature Optimization (RZTO) systems during 2020.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X